Kyverna Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Kyverna Therapeutics, Inc. (KYTX) had Debt Securities, Available-for-sale, Amortized Cost of $194.78 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $194.78M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $233.01M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $277.23M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $166.68M; Debt Securities, Available-for-sale, Amortized Cost as first filed $210.32M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $194.78M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $233.01M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $277.23M 10-Q · filed 2026-08-11 | |
| 2025-06-30 | $166.68M 10-Q · filed 2025-11-12 | $210.32M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $241.38M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $285.33M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $318.88M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $214.66M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $145.51M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $22.89M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |